Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01996826 · ClinicalTrials.gov registry record · Phase 1
A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
A Phase 1 study, sponsored by Reza Dana, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT01996826 is a Phase 1 study that has completed, run by Reza Dana, MD. The registered enrollment target is 75 participants.
The verdict
NCT01996826, a Phase 1 study, has completed, sponsored by Reza Dana, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The goal of this study is to investigate whether using bevacizumab (Avastin®) is both safe and effective at decreasing the likelihood of a high-risk corneal graft rejection. Patients who are "high-risk" for rejection have blood vessels growing from the white of the eye into the cornea (clear, front region of the eye). The medication is used at the time of surgery and in the weeks following surgery. Participants have a 50/50 chance at receiving the active study medication or a placebo medication.
Interventions
- DRUG Avastin® (bevacizumab)
- DRUG 0.9% NaCl & Refresh Liquigel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2014-04 |
| Est. Completion | 2019-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01996826
The ClinicalTrials.gov registry entry for NCT01996826 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reza Dana, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avastin® (bevacizumab) is the first listed.
NCT01996826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01996826 about?
NCT01996826 is a clinical study titled "A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival". The goal of this study is to investigate whether using bevacizumab (Avastin®) is both safe and effective at decreasing the likelihood of a high-risk corneal graft rejection. Patients who are "high-risk" for rejection have blood vessels growing from the white of the eye into the cornea (clear, front ...
What is the current status of trial NCT01996826?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2014-04. Estimated completion is 2019-04.
What interventions are being tested in trial NCT01996826?
The interventions under investigation include: Avastin® (bevacizumab) (DRUG), 0.9% NaCl & Refresh Liquigel (DRUG).
Who is sponsoring clinical trial NCT01996826?
This trial is sponsored by Reza Dana, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.